195 related articles for article (PubMed ID: 21971406)
1. High-intensity physical activity modulates diet effects on cerebrospinal amyloid-β levels in normal aging and mild cognitive impairment.
Baker LD; Bayer-Carter JL; Skinner J; Montine TJ; Cholerton BA; Callaghan M; Leverenz JB; Walter BK; Tsai E; Postupna N; Lampe J; Craft S
J Alzheimers Dis; 2012; 28(1):137-46. PubMed ID: 21971406
[TBL] [Abstract][Full Text] [Related]
2. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.
Hanson AJ; Bayer-Carter JL; Green PS; Montine TJ; Wilkinson CW; Baker LD; Watson GS; Bonner LM; Callaghan M; Leverenz JB; Tsai E; Postupna N; Zhang J; Lampe J; Craft S
JAMA Neurol; 2013 Aug; 70(8):972-80. PubMed ID: 23779114
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.
Okonkwo OC; Alosco ML; Griffith HR; Mielke MM; Shaw LM; Trojanowski JQ; Tremont G;
Arch Neurol; 2010 Jun; 67(6):688-96. PubMed ID: 20558388
[TBL] [Abstract][Full Text] [Related]
5. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.
Bayer-Carter JL; Green PS; Montine TJ; VanFossen B; Baker LD; Watson GS; Bonner LM; Callaghan M; Leverenz JB; Walter BK; Tsai E; Plymate SR; Postupna N; Wilkinson CW; Zhang J; Lampe J; Kahn SE; Craft S
Arch Neurol; 2011 Jun; 68(6):743-52. PubMed ID: 21670398
[TBL] [Abstract][Full Text] [Related]
6. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
7. Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests.
Borghys H; Van Broeck B; Dhuyvetter D; Jacobs T; de Waepenaert K; Erkens T; Brooks M; Thevarkunnel S; Araujo JA
J Alzheimers Dis; 2017; 56(2):763-774. PubMed ID: 28035921
[TBL] [Abstract][Full Text] [Related]
8. In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.
Hessen E; Kirsebom BE; Eriksson CM; Eliassen CF; Nakling AE; Bråthen G; Waterloo KK; Aarsland D; Fladby T
J Alzheimers Dis; 2019; 67(2):715-723. PubMed ID: 30614807
[TBL] [Abstract][Full Text] [Related]
9. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
11. Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial.
Hoscheidt S; Sanderlin AH; Baker LD; Jung Y; Lockhart S; Kellar D; Whitlow CT; Hanson AJ; Friedman S; Register T; Leverenz JB; Craft S
Alzheimers Dement; 2022 Mar; 18(3):457-468. PubMed ID: 34310044
[TBL] [Abstract][Full Text] [Related]
12. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
14. Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults.
Kresge HA; Liu D; Gupta DK; Moore EE; Osborn KE; Acosta LMY; Bell SP; Pechman KR; Gifford KA; Mendes LA; Wang TJ; Blennow K; Zetterberg H; Hohman TJ; Jefferson AL
J Alzheimers Dis; 2020; 74(3):965-974. PubMed ID: 32144980
[TBL] [Abstract][Full Text] [Related]
15. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
16. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
17. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
[TBL] [Abstract][Full Text] [Related]
18. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
[TBL] [Abstract][Full Text] [Related]
19. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
20. [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease].
Monge-Argilés JA; Sánchez-Payá J; Muñoz-Ruiz C; Pampliega-Pérez A; Gómez-López MJ; Rodríguez Borja E; Montoya-Gutiérrez J; Leiva-Santana C
Neurologia; 2012 Jan; 27(1):28-33. PubMed ID: 21621878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
